Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, Shanghai Haohai Biological Technology Co's average EBITDA Per Share Growth Rate was -33.70% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 2.50% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 5.00% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 1.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of Shanghai Haohai Biological Technology Co was 20.40% per year. The lowest was -12.50% per year. And the median was 4.90% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Shanghai Haohai Biological Technology Co 3-Year EBITDA Growth Rate Related Terms
FRA:5HB vs VRTX, REGN, MRNA: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Shanghai Haohai Biological Technology Co's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Haohai Biological Technology Co 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shanghai Haohai Biological Technology Co's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Shanghai Haohai Biological Technology Co's 3-Year EBITDA Growth Rate falls into.
Shanghai Haohai Biological Technology Co 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 2.50% mean?
Shanghai Haohai Biological Technology Co (FRA:5HB) has a 3-Year EBITDA Growth Rate of 2.50% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Shanghai Haohai Biological Technology Co and its competitors. This is 49% below median its historical median of 4.90. According to the industry distribution chart, Shanghai Haohai Biological Technology Co ranks #749 out of 1124 companies in the Biotechnology industry, placing it in the top 66.6%.
Is Shanghai Haohai Biological Technology Co's 3-Year EBITDA Growth Rate too high?
Shanghai Haohai Biological Technology Co's current 3-Year EBITDA Growth Rate of 2.50% is 49% below median its 10-year median of 4.90. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.65. Shanghai Haohai Biological Technology Co's value of 2.50% is 82.9% below this industry median. Based on the distribution chart, Shanghai Haohai Biological Technology Co ranks #749 out of 1124 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Shanghai Haohai Biological Technology Co has a GF Score™ of 87/100, reflecting its overall financial health beyond just this single metric.
How does Shanghai Haohai Biological Technology Co's 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shanghai Haohai Biological Technology Co ranks #749 out of 1124 companies for 3-Year EBITDA Growth Rate. This places Shanghai Haohai Biological Technology Co in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.65. Shanghai Haohai Biological Technology Co's value of 2.50% is 82.9% below this benchmark. While the company's 10-year median is 4.90 vs. the industry median of 14.65, Shanghai Haohai Biological Technology Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.65, based on 1,124 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Haohai Biological Technology Co's current 3-Year EBITDA Growth Rate of 2.50% is 82.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Shanghai Haohai Biological Technology Co and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Haohai Biological Technology Co's current 3-Year EBITDA Growth Rate is 2.50%, which is 49% below median its own 10-year median of 4.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Haohai Biological Technology Co stock overvalued right now?
Shanghai Haohai Biological Technology Co (FRA:5HB) has a current 3-Year EBITDA Growth Rate of 2.50%. The stock's GF Value™ is €2.97, compared to a current price of €1.77 — trading 40.4% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 2.50%, which is 49% below median its 10-year median of 4.90 and 82.9% below the Biotechnology industry median of 14.65. Shanghai Haohai Biological Technology Co's overall GF Score™ is 87/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Shanghai Haohai Biological Technology Co (FRA:5HB), the current 3-Year EBITDA Growth Rate is 2.50% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Haohai Biological Technology Co (FRA:5HB) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Haohai Biological Technology Co stock appears to be undervalued.
The current stock price of €1.77 is trading 40.4% below its estimated GF Value™ of €2.97.
Key valuation signals for FRA:5HB:
3-Year EBITDA Growth Rate: 2.50% (49% below median its 10-year median of 4.90)
GF Value™: €2.97 vs. price of €1.77 (40.4% below fair value)
Industry Position: 82.9% below the Biotechnology median (#749 of 1124)
No single metric tells the full story. See the FRA:5HB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Haohai Biological Technology Co Ltd is engaged in the manufacturing and sale of biologicals, medical hyaluronate, and ophthalmology products. The Company's operating activities are related to a single operating segment, which is the manufacture and sale of biologicals, medical hyaluronate, and intraocular lenses, research and development of biological engineering and pharmaceutical products, and the provision of related services. Its products are categorized into four types, comprising ophthalmology, medical aesthetics, orthopedics, and anti-adhesion. Geographically, it has operations in Mainland China, which is the key revenue driver, the United States, the United Kingdom, and other countries.
87GF Score
Get the complete analysis for FRA:5HB
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5HB has been successfully added to your 
